Analogic’s Q4, fiscal 1999, results slip

Article

Continued weakness in the Asian and South American markets helped bring in disappointing financial results for Analogic in its fiscal 1999 (end-July). Sales for the year were $279.7 million, down 10.8% from 1998’s $294.5 million, while annual net

Continued weakness in the Asian and South American markets helped bring in disappointing financial results for Analogic in its fiscal 1999 (end-July). Sales for the year were $279.7 million, down 10.8% from 1998’s $294.5 million, while annual net income was $19.5 million, compared with $23.9 million in the same period in 1998.

In the fourth quarter, Analogic had sales of $69 million, down 15.3% from the previous year’s $81.5 million. The Peabody, MA-based company’s net income for the quarter was $3.9 million, compared with $7.2 million in the fourth quarter of 1998. In addition to softness in the Asian and South American markets, Analogic also pointed to costs it sustained for new engineering projects, for start-ups, and to ensure Y2K compliance for its products.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.